Waldenström's macroglobulinemia medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 9: Line 9:
There are several different options for treating Waldenström Macroglobulinemia depending on the disease stage.<ref name=Tx>Lymphoplasmacytic lymphoma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/lymphoplasmacytic-lymphoma/?region=ab Accessed on November 6 2015 </ref>
There are several different options for treating Waldenström Macroglobulinemia depending on the disease stage.<ref name=Tx>Lymphoplasmacytic lymphoma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/lymphoplasmacytic-lymphoma/?region=ab Accessed on November 6 2015 </ref>


==Asymptomatic/Smoldering Waldenström's Macroglobulinemia==
===Asymptomatic/Smoldering Waldenström's Macroglobulinemia===
Patients who do not have symptoms and whose cancer does not seem to be progressing often do not need treatment.
Patients who do not have symptoms and whose cancer does not seem to be progressing often do not need treatment.
They can be monitored every 3-6 months - a 'wait and watch approach'.<ref name="BM">Waldenström's macroglobulinemia. Patient (2015)http://patient.info/doctor/waldenstroms-macroglobulinaemia-pro Accessed on November 10, 2015</ref>
They can be monitored every 3-6 months - a 'wait and watch approach'.<ref name="BM">Waldenström's macroglobulinemia. Patient (2015)http://patient.info/doctor/waldenstroms-macroglobulinaemia-pro Accessed on November 10, 2015</ref>


==Symptomatic Waldenström's Macroglobulinemia==
===Symptomatic Waldenström's Macroglobulinemia===
Symptomatic patients with Waldenström Macroglobulinemia are started on chemotherapy depending on the stage.<ref name="ADR">Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015)http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015</ref>
Symptomatic patients with waldenström macroglobulinemia are started on chemotherapy depending on the stage.<ref name="ADR">Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015)http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015</ref>


===Initial stage of Waldenström's macroglobulinemia associated with===
*Initial stage of waldenström's macroglobulinemia associated with
*Neuropathy,  
:*Neuropathy,  
*Anemia or cytopenias,  
:*Anemia or cytopenias,  
*Low-volume nodal involvement, and  
:*Low-volume nodal involvement, and  
*Asymptomatic splenomegaly
:*Asymptomatic splenomegaly
'''Treatment:''' Single-agent Rituximab therapy
'''Treatment:''' Single-agent Rituximab therapy


===Late stage of Waldenström's macroglobulinemia associated with===
*Late stage of waldenström's macroglobulinemia associated with
*Adenopathy,  
:*Adenopathy,  
*Symptomatic splenomegaly,  
:*Symptomatic splenomegaly,  
*Cytopenias,  
:*Cytopenias,  
*Hyperviscosity syndrome,
:*Hyperviscosity syndrome,
*Neuropathy, or
:*Neuropathy, or
*Constitutional symptoms
:*Constitutional symptoms
 
'''Treatment:'''<ref name="ADR">Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015)http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015</ref>
'''Treatment:'''<ref name="ADR">Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015)http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015</ref>


Line 111: Line 110:


==Hyperviscosity syndrome==
==Hyperviscosity syndrome==
*Plasmapheresis is recommended emergent treatment option for patients with Waldenström Macroglobulinemia who develop hyperviscosity symptoms.<ref name="ADR">Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015)http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015</ref>
*Plasmapheresis is recommended emergent treatment option for patients with waldenström macroglobulinemia who develop hyperviscosity symptoms.<ref name="ADR">Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015)http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015</ref>
*Plasmapheresis temporarily lowers IgM levels by removing some of the abnormal IgM from the blood, which makes the blood thinner.  
*Plasmapheresis temporarily lowers IgM levels by removing some of the abnormal IgM from the blood, which makes the blood thinner.  
*However, plasmapheresis does not affect the lymphoma cells.
*However, plasmapheresis does not affect the lymphoma cells.

Revision as of 07:03, 3 January 2016

Waldenström's macroglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Waldenström's macroglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Bone Marrow Aspiration and Biopsy

Electrophoresis and Immunofixation

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Waldenström's macroglobulinemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Waldenström's macroglobulinemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Waldenström's macroglobulinemia medical therapy

CDC on Waldenström's macroglobulinemia medical therapy

Waldenström's macroglobulinemia medical therapy in the news

Blogs on Waldenström's macroglobulinemia medical therapy

Directions to Hospitals Treating Waldenström's macroglobulinemia

Risk calculators and risk factors for Waldenström's macroglobulinemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]

Overview

Risk stratification determines the protocol of management used for waldenström's macroglobulinemia patients. The mainstay of therapy for asymptomatic waldenström's macroglobulinemia is watchful waiting. Symptomatic waldenström's macroglobulinemia is treated with Rituximab +/- Chemotherapy.[1]

Medical Therapy

There are several different options for treating Waldenström Macroglobulinemia depending on the disease stage.[2]

Asymptomatic/Smoldering Waldenström's Macroglobulinemia

Patients who do not have symptoms and whose cancer does not seem to be progressing often do not need treatment. They can be monitored every 3-6 months - a 'wait and watch approach'.[3]

Symptomatic Waldenström's Macroglobulinemia

Symptomatic patients with waldenström macroglobulinemia are started on chemotherapy depending on the stage.[1]

  • Initial stage of waldenström's macroglobulinemia associated with
  • Neuropathy,
  • Anemia or cytopenias,
  • Low-volume nodal involvement, and
  • Asymptomatic splenomegaly

Treatment: Single-agent Rituximab therapy

  • Late stage of waldenström's macroglobulinemia associated with
  • Adenopathy,
  • Symptomatic splenomegaly,
  • Cytopenias,
  • Hyperviscosity syndrome,
  • Neuropathy, or
  • Constitutional symptoms

Treatment:[1]

Treatment Regimen Drugs Side effects

CHOP-R regimen

  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone
  • Rituximab
  • Nausea
  • Alopecia
  • Granulocytopenia

Ibrutinib

  • Ibrutinib
  • Fatigue
  • Cytopenia

Rituximab

  • Rituximab
  • Infusion related reaction
  • Infections

FR regimen

  • Fludarabine
  • Rituximab
  • Neutropenia (63%)
  • Thrombocytopenia
  • Pneumonia

BDR regimen

  • Bortezomib
  • Dexamethasone
  • Rituximab
  • Peripheral Neuropathy - reversible in 61% of patients

DRC regimen

  • Dexamethasone
  • Rituximab
  • Cyclophosphamide
  • Neutropenia

CR regimen

  • Cladribine
  • Rituximab
  • Anemia
  • Neurological symptoms
  • Symptomatic cryoglobulinemia
  • Thrombocytopenia

Hyperviscosity syndrome

  • Plasmapheresis is recommended emergent treatment option for patients with waldenström macroglobulinemia who develop hyperviscosity symptoms.[1]
  • Plasmapheresis temporarily lowers IgM levels by removing some of the abnormal IgM from the blood, which makes the blood thinner.
  • However, plasmapheresis does not affect the lymphoma cells.
  • Plasmapheresis is usually given until chemotherapy starts to work.
  • Plasmapheresis is combined with chemotherapy to control the disease for a longer period of time.

References

  1. 1.0 1.1 1.2 1.3 Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015)http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015
  2. Lymphoplasmacytic lymphoma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/lymphoplasmacytic-lymphoma/?region=ab Accessed on November 6 2015
  3. Waldenström's macroglobulinemia. Patient (2015)http://patient.info/doctor/waldenstroms-macroglobulinaemia-pro Accessed on November 10, 2015

Template:WH Template:WS